Guardant Health (NASDAQ:GH) Price Target Raised to $75.00 at Leerink Partners

Guardant Health (NASDAQ:GH) had its price target raised by Leerink Partners from $70.00 to $75.00 in a report published on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

GH has been the topic of several other reports. Mizuho increased their price target on Guardant Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Friday, June 13th. Guggenheim upped their target price on Guardant Health from $56.00 to $67.00 and gave the stock a “buy” rating in a research note on Thursday. Wolfe Research upgraded Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target for the company in a research report on Thursday. Cowen restated a “buy” rating on shares of Guardant Health in a research report on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Guardant Health from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating and twenty-two have issued a Buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $64.75.

Guardant Health Trading Up 4.4%

Shares of NASDAQ GH opened at $60.18 on Thursday. Guardant Health has a 12 month low of $20.14 and a 12 month high of $68.00. The company has a 50 day simple moving average of $55.34 and a two-hundred day simple moving average of $48.72. The stock has a market cap of $7.51 billion, a price-to-earnings ratio of -17.96 and a beta of 1.46.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. During the same quarter in the previous year, the company earned ($0.84) EPS. The firm’s revenue was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. Analysts forecast that Guardant Health will post -2.9 EPS for the current year.

Insider Transactions at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $54.16, for a total value of $117,256.40. Following the completion of the sale, the director owned 851 shares of the company’s stock, valued at approximately $46,090.16. The trade was a 71.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Amirali Talasaz sold 100,000 shares of the company’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the transaction, the chief executive officer owned 1,971,830 shares of the company’s stock, valued at $100,326,710.40. This represents a 4.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 402,691 shares of company stock valued at $23,069,965 in the last three months. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Guardant Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC increased its position in shares of Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares in the last quarter. American Century Companies Inc. boosted its stake in Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock worth $4,439,000 after purchasing an additional 282 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after buying an additional 334 shares in the last quarter. Main Management ETF Advisors LLC grew its holdings in shares of Guardant Health by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock worth $1,106,000 after buying an additional 348 shares in the last quarter. Finally, HighTower Advisors LLC raised its position in shares of Guardant Health by 0.9% in the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock valued at $2,177,000 after buying an additional 469 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.